The cost and risk of failure of traditional drug discovery approaches means people with rare diseases tend to be sidelined by the pharmaceutical industry who struggle to justify investment in treatments for smaller populations. This is one of the reasons why Dr. Tim Guilliams decided to co-found a start-up dedicated to help those patients suffering from such conditions.

Get full access to our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture